Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Nicod

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 20, 2016
Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countriesElena Nicod
Health Policy (Amsterdam, Netherlands)|October 24, 2012
Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisionsElena Nicod, Panos Kanavos
International Journal of Technology Assessment in Health Care|September 15, 2016
SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENTElena Nicod, Panos Kanavos
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 19, 2012
What is wrong with orphan drug policies? Suggestions for ways forwardPanos Kanavos, Elena Nicod
Health Policy (Amsterdam, Netherlands)|January 3, 2016
Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods studyElena Nicod, Panos Kanavos
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 4, 2024
Rare Diseases: Economic Evaluation and Policy ConsiderationsBrian E Rittenhouse, Elena Nicod
International Journal of Technology Assessment in Health Care|September 28, 2020
The estimation of health state utility values in rare diseases: overview of existing techniquesMichela Meregaglia, Elena Nicod, Michael Drummond
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 6, 2022
The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping reviewMichela Meregaglia, Elena Nicod, Michael Drummond
The Patient|January 19, 2021
The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology AssessmentAmanda Whittal, Michela Meregaglia, Elena Nicod
Health Economics, Policy, and Law|September 7, 2019
Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods studyElena Nicod, Laia Maynou, Erica Visintin, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 20, 2016
Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countriesElena Nicod
Health Policy (Amsterdam, Netherlands)|October 24, 2012
Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisionsElena Nicod, Panos Kanavos
International Journal of Technology Assessment in Health Care|September 15, 2016
SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENTElena Nicod, Panos Kanavos
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 19, 2012
What is wrong with orphan drug policies? Suggestions for ways forwardPanos Kanavos, Elena Nicod
Health Policy (Amsterdam, Netherlands)|January 3, 2016
Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods studyElena Nicod, Panos Kanavos
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 4, 2024
Rare Diseases: Economic Evaluation and Policy ConsiderationsBrian E Rittenhouse, Elena Nicod
International Journal of Technology Assessment in Health Care|September 28, 2020
The estimation of health state utility values in rare diseases: overview of existing techniquesMichela Meregaglia, Elena Nicod, Michael Drummond
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 6, 2022
The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping reviewMichela Meregaglia, Elena Nicod, Michael Drummond
The Patient|January 19, 2021
The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology AssessmentAmanda Whittal, Michela Meregaglia, Elena Nicod
Health Economics, Policy, and Law|September 7, 2019
Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods studyElena Nicod, Laia Maynou, Erica Visintin, et al.
Pageof 3